Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan

PHASE2CompletedINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Alogliptin

Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.

DRUG

Alogliptin

Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.

DRUG

Alogliptin

Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.

DRUG

Voglibose

Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY